
    
      A Phase II, open-label, extesion study. Following a Screening period of up to one month,
      subjects previously treated with PRO044, and eligible for enrolment in PRO044-CLIN-02, will
      be allocated to one of three groups to receive either 6 mg/kg or 9 mg/kg PRO044 weekly by IV
      infusion or 6 mg/kg weekly by SC injection for 48 weeks.

      Safety and tolerability, pharmacokinetics (PK), pharmacodynamic (PD) and efficacy assessments
      will be conducted at regular intervals throughout the study.
    
  